$CMPS news
The latest CMPS stock news: headlines, filings, AI summaries and sentiment for $CMPS, updated around the clock.
- Compass Pathways to Submit FDA New Drug Application for COMP360 Within Two Weeks
- Compass Pathways Reports Q3 2026 Financial Results and COMP360 Regulatory Update
- Compass Pathways Shares Recover Following Third Quarter Earnings Results
- COMPASS Pathways plc - 8-K Filing
- COMPASS Pathways plc - 10-Q Filing
- COMPASS Pathways (CMPS) Scheduled to Report Q3 2026 Earnings
- Definium's LSD-Based Treatment Shows Positive Results in Second Anxiety Trial
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal; Cathie Wood Favors Competitor Compass Pathways
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal; Cathie Wood Shifts Focus to Compass Pathways
- AtaiBeckley shares surge amid reported acquisition talks with Eli Lilly
- Neuronetics (STIM) Announces Participation in B. Riley Summit and Leadership Appointment
- Compass Pathways Reports Positive Phase 3 Data on COMP360 for Treatment-Resistant Depression
- COMPASS Pathways plc - 8-K Filing
- Trump Administration Accelerates Psychedelic Drug Research for Mental Health Treatment
- COMPASS Pathways plc - 8-K Filing
- COMPASS Pathways plc - 10-Q Filing
- COMPASS Pathways plc - 8-K Filing
- FDA Grants Rolling Review and CNPV Designation to Compass Pathways for TRD Treatment
- Trump's Executive Order May Accelerate Psychedelic Therapy Regulation
- Trump's Executive Order on Psychedelics Seen as Validation for Investors
- Trump Signs Executive Order to Accelerate Psychedelic Research and Regulation
- Compass Pathways Stock Surges 40% Following White House Executive Order on Psychedelic Therapies
- Compass Pathways Stock Surges 40% Following White House Executive Order on Psychedelic Therapies
- Trump Fast-Tracks Psychedelic Treatments, Boosting Biotech Stocks
- Psychedelic Stocks and Other Major Market Movers on Monday
- Psychedelic Stocks Rise Following Trump's Order to Accelerate PTSD Research